|
시장보고서
상품코드
1846109
PTA 풍선 카테터 시장 : 재료 유형, 용도, 최종사용자, 지역별(2024-2031년)PTA Balloon Catheter Market By Material Type (Polyurethane, Nylon), Application (Peripheral Artery Disease, Coronary Artery Disease), End-User (Hospital, Ambulatory Surgical Centers) & Region for 2024-2031 |
||||||
PTA(경피적 관상동맥 성형술)용 풍선 카테터 시장은 심혈관 질환 유병률 증가, 저침습 치료에 대한 수요 증가, 풍선 카테터 기술 발전, 말초동맥질환(PAD) 치료에 대한 인식 제고 등이 배경이 되고 있습니다. 이에 따라 시장 규모는 2024년 29억 8,000만 달러를 돌파하고, 2031년에는 약 11억 6,000만 달러에 달할 것으로 전망됩니다.
메드트로닉, 보스턴 사이언티픽 코퍼레이션, 애보트 래버러토리스, 쿡 메디컬 등이 주요 시장 진입 기업입니다. 북미와 유럽은 정교한 의료 인프라를 갖추고 있어 주요 지역으로 꼽히지만, 의료 시설의 개선과 의료비 증가에 따라 아시아태평양이 크게 증가할 것으로 예상됩니다. PTA 풍선 카테터에 대한 수요가 증가함에 따라 시장은 2024년부터 2031년까지 CAGR 9.70%로 성장할 것입니다.
PTA 풍선 카테터 시장 정의/개요
PTA(Percutaneous Transluminal Angioplasty) 풍선 카테터는 좁아지거나 막힌 혈관을 넓히는 데 사용되는 의료기기입니다. PTA 풍선 카테터는 끝부분에 작은 풍선이 달린 유연한 카테터로 구성되어 있으며, 풍선을 부풀려 플라크를 혈관벽에 밀어 넣어 혈액순환을 촉진합니다.
PTA 풍선 카테터는 경피적 경관 혈관성형술(PTA)에 사용되어 좁아지거나 막힌 혈관(일반적으로 동맥)을 넓히고 적절한 혈류를 회복시키는 데 사용됩니다. PTA는 말초동맥질환(PAD) 등의 질병을 치료하고, 혈액순환을 촉진하며, 환부의 통증과 경련 등의 증상을 완화하는 데 매우 중요합니다.
PTA(Percutaneous Transluminal Angioplasty) 풍선 카테터의 향후 사용은 심혈관질환률의 증가, 최소침습 수술의 발전, 노인 인구의 증가로 인해 증가할 것으로 예상되며, 이 모든 것이 환자의 예후를 개선하고 회복 시간을 단축하는 효과적인 혈관 혈관 중재에 대한 수요를 촉진하고 있습니다.
PTA 풍선 카테터에서 폴리우레탄의 선택 증가는 시장 확대의 원동력이 될 것으로 예상됩니다. 폴리우레탄은 생체적합성, 유연성, 내구성이 뛰어나 의료용에 이상적이기 때문에 인기가 높습니다. 다양한 해부학적 특징에 적응할 수 있기 때문에 혈관 질환 치료에서 풍선 카테터의 효과가 높아집니다.
또한, 폴리우레탄은 펑크와 찢어짐에 강하기 때문에 카테터가 파손될 가능성이 낮아 환자의 안전과 치료 결과를 향상시킵니다. 재료 과학이 발전함에 따라 폴리우레탄 기반 카테터의 기능은 더욱 향상되고, 의료 산업에서의 사용도 증가할 것으로 예상됩니다. 이러한 추세는 심혈관질환의 유병률 증가 및 최소침습 수술에 대한 수요와 함께 PTA 풍선 카테터 시장을 크게 견인할 것으로 보입니다.
카테터 치료에 수반되는 위험과 위험은 PTA 풍선 카테터 시장의 확대를 저해할 수 있습니다. 감염, 혈관 손상, 혈전증, 재협착은 모두 환자와 의료진이 이러한 치료를 받는 것을 방해하는 잠재적 합병증입니다. 또한, 카테터 치료를 안전하고 성공적으로 수행하기 위해서는 전문적인 지식이 필요하기 때문에 숙련된 의료진 확보가 어려워 시장 성장에 걸림돌이 될 수 있습니다.
악의적인 사고에 대한 우려로 인해 규제 당국의 감시가 강화되고 승인 절차가 엄격해져 신제품 출시가 지연될 수 있습니다. 또한, 비침습적 대안을 찾는 환자들의 의지가 PTA 풍선 카테터에 대한 수요를 감소시킬 가능성도 있습니다. 이러한 장애물을 해결하기 위해서는 카테터 설계의 지속적인 발전, 시술 절차의 개선, 환자 모니터링의 강화가 보다 안전하고 효과적인 치료 결과를 보장하고 시장의 성장을 유지하는 데 필수적입니다.
The PTA (Percutaneous Transluminal Angioplasty) Balloon Catheter Market is being driven by rising cardiovascular disease prevalence, increased demand for minimally invasive procedures, technological advancements in balloon catheters, and growing awareness of peripheral artery disease (PAD) treatments. This is likely to enable the market size surpass USD 2.98 Billion valued in 2024 to reach a valuation of around USD 1.16 Billion by 2031.
Medtronic, Boston Scientific Corporation, Abbott Laboratories and Cook Medical are among the market's leading participants. North America and Europe are the leading regions due to sophisticated healthcare infrastructure, but the Asia-Pacific region is predicted to increase significantly as healthcare facilities improve and healthcare expenditure rises. The rising demand for PTA balloon catheter is enabling the market grow at a CAGR of 9.70% from 2024 to 2031.
PTA Balloon Catheter Market: Definition/ Overview
A PTA (Percutaneous Transluminal Angioplasty) balloon catheter is a medical device used to widen blood arteries that are restricted or occluded. It consists of a flexible catheter with a tiny balloon at the tip that is inflated to compress plaque against the vascular wall, so increasing blood circulation.
PTA balloon catheters are used in percutaneous transluminal angioplasty (PTA) to widen narrowed or obstructed blood vessels, usually arteries, and restore appropriate blood flow. They are critical for treating illnesses such as peripheral artery disease (PAD), increasing circulation, and alleviating symptoms such as pain and cramping in affected limbs.
The future use of PTA (Percutaneous Transluminal Angioplasty) balloon catheters is expected to increase due to rising cardiovascular disease rates, advances in minimally invasive procedures and a growing geriatric population, all of which are driving demand for effective vascular interventions with better patient outcomes and shorter recovery times.
The growing choice for polyurethane in PTA balloon catheters is expected to drive market expansion. Polyurethane is popular because of its high biocompatibility, flexibility, and durability, making it ideal for medical applications. Its capacity to conform to varied anatomical features increases the effectiveness of balloon catheters in treating vascular diseases.
Furthermore, polyurethane's resilience to punctures and tears lowers the likelihood of catheter failure, which improves patient safety and outcomes. As material science advances, polyurethane-based catheters are predicted to function even better, increasing their use in the medical industry. This trend, together with the rising incidence of cardiovascular illnesses and the demand for minimally invasive procedures, will significantly boost the PTA balloon catheter market.
Risks and hazards connected with catheterization operations may impede the expansion of the PTA balloon catheter market. Infections, vascular injury, thrombosis, and restenosis are all potential complications that may prevent patients and healthcare providers from undergoing these treatments. Furthermore, the need for specialized expertise to execute catheterizations safely and successfully may limit the availability of skilled practitioners, weighing on market growth.
Concerns about bad incidents may result in increased regulatory scrutiny and tougher approval processes, thereby delaying the launch of new goods. Furthermore, patients' desire for non-invasive options may diminish demand for PTA balloon catheters. To address these obstacles, continued advances in catheter design, improved procedural procedures, and greater patient monitoring are critical to assuring safer and more effective outcomes, which will sustain market growth.
The enhanced biocompatibility and flexibility are key factors boosting the polyurethane segment of the PTA balloon catheter market. Polyurethane's biocompatibility reduces the chance of adverse responses in patients, making it a favoured material for medical equipment. Its suppleness enables the balloon catheter to more successfully negotiate intricate arterial paths, increasing the overall efficacy of the treatment. These qualities not only improve patient safety, but also optimize catheter function during interventions.
Furthermore, polyurethane's resilience and resistance to punctures or tears add to its increasing popularity. As the demand for minimally invasive procedures rises, polyurethane's benefits over other materials are projected to fuel segment dominance, resulting in greater market adoption and innovation in catheter technology.
The increasing prevalence of coronary artery disease (CAD) and the requirement for frequent interventions will boost the application sector of the PTA balloon catheter market. CAD is a primary cause of cardiovascular events, necessitating the routine use of PTA balloon catheters for angioplasty treatments to restore blood flow and relieve symptoms.
The increasing prevalence of CAD creates a huge demand for effective and dependable treatment alternatives. Furthermore, frequent interventions for CAD patients encourage continued use and improvement in PTA balloon catheter devices. As the population ages and lifestyle-related risk factors increase, the need for these operations is likely to rise. This trend is projected to drive continuous market expansion for PTA balloon catheters, particularly in the coronary artery disease application category. Thus, enabling the segment hold major share in the market growth over the forecast period.
ropel the PTA balloon catheter market in North America. Cardiovascular disorders, such as coronary artery disease and peripheral artery disease, are among the region's most pressing health concerns, necessitating an increase in demand for efficient treatment alternatives. The enormous patient population necessitates frequent interventions, increasing the demand for PTA balloon catheters.
Furthermore, North America's excellent healthcare infrastructure and rapid technological adoption encourage the use of novel medical equipment. The existence of significant medical device manufacturers and robust healthcare policies contribute to market growth. As knowledge of cardiovascular health increases and treatment options expand, the market for PTA balloon catheters in North America is likely to dominate over the forecast period.
Increasing healthcare access in emerging economies will drive the Asia-Pacific PTA balloon catheter market. As healthcare infrastructure improves and access to medical services grows, more patients in these economies receive prompt therapies for cardiovascular illnesses. Rising awareness and government measures to improve healthcare delivery contribute to more use of modern medical devices, such as PTA balloon catheters.
Furthermore, the increasing prevalence of cardiovascular disorders in these locations raises the demand for better treatment alternatives. Increased investment in healthcare facilities, combined with the development of low-cost medical gadgets, drives market expansion. As these economies expand their healthcare capacities, Asia-Pacific's PTA balloon catheter market is likely to rise significantly.
The PTA balloon catheter market is a dynamic and competitive space, characterized by a diverse range of players vying for market share. These players are on the run for solidifying their presence through the adoption of strategic plans such as collaborations, mergers, acquisitions, and political support. The organizations are focusing on innovating their product line to serve the vast population in diverse regions.
Some of the prominent players operating in the PTA balloon catheter market include:
Medtronic plc
Terumo Corporation
Boston Scientific Corporation
Natec Medical
Cardinal Health
Cook Medical
Biotronik
Abbott
Andratec
Surmodics, Inc.
PTA Balloon Catheter Market Latest Developments
In January 2024, Cook Medical announced that its Slip-Cath Beacon Tip hydrophilic selective catheter is now available in the United States and Canada.
In June 2023, Cook Medical expanded its Advance Serenity hydrophilic percutaneous transluminal angioplasty balloon catheter product line with new sizes and locations.
In March 2023, BrosMed received CE MDR approval for its Tiche 0.035 High-Pressure PTA Balloon Dilatation Catheter. The catheter is intended to treat severe calcified peripheral vascular disease and hard AV cases under the European Medical Device Regulation (MDR).